– USA, TX – Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a development-stage biotechnology company, today announced its new name to Spyre Therapeutics, Inc. (NASDAQ: SYRE).
The Company announced the appointment of Dr. Cameron Turtle (DPhil) to its Board of Directors as CEO, while also announcing the appointments of Jeff Albers and Laurie Stelzer to its Board of Directors.
“We are thrilled to welcome Jeff and Laurie, whose expertise will strengthen our Board as we pursue this new journey as Spyre and focus our efforts with the goal of breaking the efficacy ceiling in IBD.” said Board Chairman, Russell Cox.Laurie Stelzer will also join the audit committee as Chair.
Concurrently, Hunter Smith and Ivana Magovčević-Liebisch have resigned from the Board effective November 22, 2023.
About Dr. Cameron Turtle
Dr. Turtle was COO of Spyre and previously served as CSO of BridgeBio Pharma, Inc. and CBO of Eidos Therapeutics, Inc.
About Jeffrey Albers
Jeff Albers has over 25 years of experience working in the biopharmaceutical industry. He currently serves as the Chairman of the Board at Blueprint Medicines, where he served as CEO from 2014-2022 and grew the business into a leading precision medicine company with global commercial operations, two FDA-approved therapies, and a promising pipeline.
About Laurie Stelzer
Laurie Stelzer has over 25 years of experience supporting the finance functions of biopharma companies. She currently serves as CFO at ReNAgade Therapeutics and previously served as CFO of Mirati Therapeutics and as CFO of Arena Pharmaceuticals, where she helped lead the growth of the company towards its $6.7B acquisition by Pfizer.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create the next generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.
SOURCE: https://www.aeglea.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.